Nebraska Hematology-Oncology (NHO), an independent, community-based cancer care team of healthcare professionals in Lincoln, Neb., is proud to announce a strategic partnership with Revive Research Institute – marking a significant milestone in the advancement of cancer care and research.

NHO Revive Research Institute (NHO Revive) matches Nebraska Hematology-Oncology's expertise in evidence-based treatments for cancer and blood disorders and Revive Research Institute’s clinical trial operation excellence to pioneer groundbreaking therapies and expand the scope of oncology clinical trials. This partnership signifies a significant step forward in the fight against cancer, a shared mission between the two institutes. 

"Our mission at Revive Research Institute is to revolutionize healthcare through collaborative research efforts," said Dr. Mazhar Jaffry, CEO of Revive Research Institute. "Partnering with Nebraska Hematology-Oncology allows us to combine our strengths and accelerate the development of life-saving treatments." 

This collaboration between NHO and Revive Research Institute will offer patients access to a wide range of oncology and hematology clinical trials, providing advanced treatment options and consequently hope. With a patient-centric approach, NHO Revive aims to improve patient outcomes, and bring a meaningful change in the lives of those battling cancer. 

"Nebraska Hematology-Oncology is committed to delivering exceptional cancer care to our patients," said Dr. Kailash Mosalpuria, Medical Oncologist at NHO. "Through our collaboration with Revive Research Institute, we are expanding our capabilities in oncology and hematology clinical trials and bringing novel treatments to the communities we serve." 

“This collaboration opens the door for more clinical trials that can benefit our patients right here in Nebraska,” commented NHO Clinical Director of Research Ashley Waldrep. “By taking part in these trials, it allows eligible patients with various types of cancer to have another option for treatment. The treatment offered within a trial is closely monitored for safety and efficacy, and what we learn from the trials today will play a vital role in improving cancer care, which will benefit all other patients for decades to come.”

At the core of its endeavor, NHO Revive will continue to prioritize patient care and safety while striving for excellence in oncology research. Together, NHO and Revive are dedicated to advancing medical discoveries and making a meaningful impact in the fight against cancer. 

For more information about Nebraska Hematology-Oncology and its collaboration with Revive Research Institute, please visit nhoreviveresearch.com.